Journal Mobile Options
Table of Contents
Vol. 41, No. 1, 1999
Issue release date: January 1999
Eur Neurol 1999;41:3–9
(DOI:10.1159/000007990)

Peripheral Facial Palsy: Etiology, Diagnosis and Treatment

Roob G. · Fazekas F. · Hartung H.-P.
Department of Neurology, Karl Franzens University, Graz, Austria

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Treatment options for peripheral facial palsy (PFP) are an often discussed problem in neurologic practice. Following a short description of the complex anatomy of the seventh cranial nerve we therefore review possible etiologies in the context of leading clinical signs, with idiopathic PFP or Bell’s palsy (BP) being most frequent. A rather typical clinical course of BP allows to focus differential diagnostic workup predominantly on the rapid identification of treatable infections such as with Herpes zoster or Borrelia burgdorferi. Neuroimaging studies are needed only in case of trauma, with slowly developing PFP or in the presence of associated signs and symptoms. As BP is characterized by an overall high rate of spontaneous recovery, major emphasis has to be put on avoiding complications by protecting the eye. Meta-analysis of four randomized controlled studies suggests a marginal benefit of steroids concerning eventual achievement of complete recovery. Beneficial effects of a combination of acyclovir and prednisone have also been claimed. While such therapies may be considered in patients with a presumptive bad prognosis, more general recommendations on medical treatment of BP will have to await further trials.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Bell C: The nervous system of the human body (appendix; case 49). London, Longman, Rees, Orme, Brown & Green, 1830, pp 85–87.
  2. Peitersen E: The natural history of Bell’s palsy. Am J Otol 1982;4:107–111.
  3. Karnes WE: Diseases of the seventh cranial nerve; in Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF (eds): Peripheral Neuropathy, ed 3. Philadelphia, Saunders, 1993, pp 818–836.
  4. Adour KK: Otological complications of herpes zoster. Ann Neurol 1994;35(suppl):S62–S64.
  5. Murakami S, Mizobuchi M, Nakashiro Y, Doi T, Hato N, Yanagihara N: Bell palsy and herpes simplex virus: Identification of viral DNA in endoneurial fluid and muscle. Ann Intern Med 1996;124:27–30.
  6. Morgan M, Nathwani D: Facial palsy and infection: The unfolding story. Clin Infect Dis 1992;14:263–271.
  7. Hydén D, Roberg M, Forsberg P, Fridell E, Frydén A, Linde A, Ödkvist L: Acute ‘idiopathic’ peripheral facial palsy: Clinical, serological, and cerebrospinal fluid findings and effects of corticosteroids. Am J Otolaryngol 1993;14:179–186.
  8. Kuiper H, Devriese P, de Jongh BM, Vos K, Dankert J: Absence of Lyme borreliosis among patients with presumed Bell’s palsy. Arch Neurol 1992;49:940–943.
  9. Keane JR: Bilateral seventh nerve palsy: Analysis of 43 cases and review of the literature. Neurology 1994;44:1198–1202.
  10. Fukazawa T, Moriwaka F, Hamada K, Hamada T, Tashiro K: Facial palsy in multiple sclerosis. J Neurol 1997;244:631–633.
  11. Williamson IG, Whelan TR: The clinical problem of Bell’s palsy: Is treatment with steroids effective? Br J Gen Pract 1996;46:743–747.
  12. Adour KK: Current concepts in neurology: Diagnosis and management of facial palsy. N Engl J Med 1982;307:348–351.
  13. Katusic SK, Beard CM, Wiederholt WC, Bergstralh EJ, Kurland LT: Incidence, clinical features and prognosis in Bell’s palsy, Rochester Minnesota, 1968–1982. Ann Neurol 1986;20:222–227.
  14. Savettieri G, Salemi G, Rocca WA, Meneghini F, Santangelo R, Morgante L, Coraci MA, Reggio A, Grigoletto F, Di Perri R: Incidence and lifetime prevalence of Bell’s palsy in two Sicilian municipalities. Sicilian Neuro-Epidemiologic Study (SNES) Group. Acta Neurol Scand 1996;94:71–75.
  15. Qiu WW, Yin SS, Stucker FJ, Aarstad RF, Nguyen HH: Time course of Bell palsy. Arch Otolaryngol Head Neck Surg 1996;22:967–972.
  16. Rosler KM, Magistris MR, Glocker FX, Kohler A, Deuschl G, Hess CW: Electrophysiologic characteristics of lesions in facial palsies of different etiologies. A study using electrical and magnetic stimulation techniques. Electroencephalogr Clin Neurophysiol 1995;97:355–368.
  17. Tschiassny K: Eight syndromes of facial paralysis and their significance in locating the lesion. Ann Otol Rhinol Laryngol 1953;62:677–683.
  18. Hughes GB: Practical management of Bell’s palsy. Otolaryngol Head Neck Surg 1990;102:658–663.
  19. Devriese PP, Schumacher T, Scheide A, de Jongh RH, Houtkooper JM: Incidence, prognosis and recovery of Bell’s palsy. A survey of about 1,000 patients (1974–1983). Clin Otolaryngol 1990;15:15–27.
  20. Rickenmann J, Jaquenod C, Cerenko D, Fisch U: Comparative value of facial nerve grading systems. Otolaryngol Head Neck Surg 1997;117:322–325.
  21. Saatci I, Sahintürk F, Sennaroglu L, Boyvat F, Gürsel B, Besim A: MRI of the facial nerve in idiopathic facial palsy. Eur Radiol 1996;6:631–636.
  22. Brandle P, Sartoretti-Schefer S, Bohmer A, Wichmann W, Fisch U: Correlation of MRI, clinical, and electroneurographic findings in acute facial nerve palsy. Am J Otol 1996;17:154–161.
  23. Berrettini S, Bianchi MC, Segnini G, Sellari-Franceschini S, Bruschini P, Montanaro D: Herpes zoster oticus: Correlations between clinical and MRI findings. Eur Neurol 1998;39:26–31.
  24. Moseley I: Imaging the adult brain. J Neurol Neurosurg Psychiatry 1995;58:7–21.
  25. Marenda SA, Olsson JE: The evaluation of facial paralysis. Otolaryngol Clin North Am 1997;30:669–682.
  26. Albisetti M, Schaer G, Good M, Boltshauser E, Nadal D: Diagnostic value of cerebrospinal fluid examination in children with peripheral facial palsy and suspected Lyme borreliosis. Neurology 1997;49:817–824.
  27. Furuta Y, Fukuda S, Suzuki S, Takasu T, Inuyama Y, Nagashima K: Detection of varicella-zoster virus DNA in patients with acute peripheral facial palsy by the polymerase chain reaction, and its use for early diagnosis of zoster sine herpete. J Med Virol 1997;52:316–319.
  28. Seddon HJ: Three types of nerve injury. Brain 1943;66:237–241.
  29. Coker NJ: Facial electroneurography: Analysis of techniques and correlation with degenerating motoneurons. Laryngoscope 1992;102:747–759.
  30. May M, Blumenthal F, Klein SR: Acute Bell’s palsy: Prognostic value of evoked electromyography, maximal stimulation, and other electrical tests. Am J Otol 1983;5:1–7.

    External Resources

  31. Sinha PK, Keith RW, Pensak ML: Predictability of recovery from Bell’s palsy using evoked electromyography. Am J Otol 1994;15:769–771.
  32. Mountain RE, Murray JAM, Quaba A, Maynard C: The Edinburgh facial palsy clinic – A review of three years’ activity. J R Coll Surg Edinb 1994;39:275–279.
  33. Sansone V, Boynton J, Palenski C: Use of gold weights to correct lagophthalmus in neuromuscular disease. Neurology 1997;48:1500–1503.
  34. Burgess LPA, Yim DWS, Lepose ML: Bell’s palsy: The steroid controversy revisited. Laryngoscope 1984;94:1472–1476.
  35. Taverner D: Cortisone treatment of Bell’s palsy. Lancet 1954;ii:1052–1054.
  36. May M, Wette R, Hardin WB, Sullivan J: The use of steroids in Bell’s palsy: A prospective controlled study. Laryngoscope 1976;86:1111–1112.
  37. Wolf SM, Wagner JH, Davidson S, Forsythe A: Treatment of Bell’s palsy with prednisolone: A prospective randomized study. Neurology 1978;28:158–161.

    External Resources

  38. Austin JR, Peskind SP, Austin SG, Rice DH: Idiopathic facial nerve paralysis: A randomised double blind controlled study of placebo versus prednisolone. Laryngoscope 1993;103:1326–1333.
  39. Stennert E: Pathomechanisms in cell metabolism: A key to treatment of Bell’s palsy. Ann Otol Rhinol Laryngol 1981;90:577–580.
  40. Kawai M, Inamura H, Koike Y: On the conservative treatment of Bell’s palsy. Acta Otolaryngol 1988;446:106–110.
  41. Mezzina C, De Grandis D, Calvani M, Marchionni A, Pomes A: Idiopathic facial paralysis: New therapeutic prospects with acetyl-L-carnitine. Int J Clin Pharmacol Res 1992;12:299–304.

    External Resources

  42. Adour KK, Ruboylanes JM, Von Doersten PG, Byl FM, Trent CS, Quesenberry CP Jr, Hitchcock T: Bell’s palsy treatment with acyclovir and prednisone compared with prednisone alone: A double-blind, randomized, controlled trial. Ann Otol Rhinol Laryngol 1996;105:371–378.
  43. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J: A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994;330:896–900.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50